Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in
combination with olanzapine ,palonosetron and dexamethasone for the prevention of
chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately
emetogenic chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University